Tag

Medtronic

All articles tagged with #medtronic

business1 month ago•46 min saved

Medtronic reports decade-best revenue growth, boosts dividend and guides strongly for FY27

Medtronic reported Q4 FY26 revenue of $9.807B (up 9.9% YoY; 6.6% organic) and FY26 revenue of $36.364B (up 8.4%; 5.8% organic). GAAP EPS rose to $0.96 in Q4; non-GAAP EPS was $1.55. The company raised its quarterly dividend to $0.72 ($2.88 annual), marking the 49th consecutive increase. For FY27, Medtronic guided 6.75%-7.25% organic revenue growth and $5.90-$6.00 in non-GAAP EPS, reflecting the 53rd week, diabetes consolidation, and ongoing M&A activity. It highlighted strength in CRM, CST and Surgical, plus tuck-in deals (CathWorks, Scientia Vascular, SPR Therapeutics) and growth platforms (Affera, Hugo, Stealth AXiS) as momentum builds into 2027.

via Medtronic|

#business #dividend #earnings

business11 months ago•2 min saved

Activist Investor Sparks Strategic Changes at Medtronic

Medtronic's stock fell over 4% after announcing new board appointments to appease activist investor Elliott Management, despite reporting a strong fiscal first quarter with sales beating expectations and raising its profit outlook. The company added new directors with extensive medical device experience and is focusing on growth and operational improvements, which Elliott believes will lead to sustained earnings growth.

via Investor's Business Daily|

#activist-investor #business #elliott-management

health1 year ago•8 min saved

Revolutionizing AFib Treatment: The Rise of Pulsed Field Ablation

Medtronic, Boston Scientific, and Johnson & Johnson MedTech are racing to commercialize pulsed field ablation (PFA) technology, a safer and quicker treatment for atrial fibrillation (AFib). PFA uses electric pulses to ablate cardiac tissue, reducing procedure time and complications compared to older methods. The technology is expected to drive significant growth in the medtech industry, with global sales projected to surpass $1.3 billion. The new systems, including Boston Scientific's Farapulse and Medtronic's PulseSelect, have received FDA approval, marking a shift in AFib treatment.

via Star Tribune|

#atrialfibrillation #bostonscientific #health

business2 years ago•1 min saved

Medtronic Reports Strong Q4 Sales, Hikes Dividend Despite Stock Drop

Medtronic reported strong Q4 2024 earnings with sales of $8.59 billion, surpassing expectations. The company saw broad-based organic revenue growth across all segments, particularly in neurology devices. Adjusted EPS was $1.46, slightly above consensus. Medtronic also increased its quarterly dividend to $0.70 per share and provided optimistic guidance for fiscal year 2025, forecasting adjusted EPS of $5.40-$5.50 and organic revenue growth of 4%-5%. Despite the positive results, MDT shares were down 2.64%.

via Yahoo Finance|

#business #dividend-increase #medtronic

finance2 years ago•2 min saved

Medtronic Stock Falls Despite Strong Q4 Earnings and Dividend Hike

Medtronic's stock fell 2.8% despite beating earnings expectations due to underwhelming year-over-year sales growth and a significant drop in GAAP earnings. Investors are concerned about the company's high valuation and modest growth forecast for fiscal 2025, leading to a sell-off.

via Yahoo Finance|

#earnings-report #finance #investment

financeinvesting2 years ago•3 min saved

"Unveiling the Impact of AI in Healthcare: Stocks, Implementation, and Ethical Considerations"

The potential of artificial intelligence (AI) in healthcare has attracted investor attention, with the market expected to reach $148 billion by 2029. Moderna, known for its COVID-19 vaccine, is utilizing AI in its pipeline and research processes, potentially leading to faster product development and new revenue sources. Medtronic, a medical device giant, has already secured approvals for AI-powered products and established an AI center of excellence, positioning itself for growth in the AI healthcare market. Both companies present long-term investment potential in the evolving landscape of AI in healthcare.

via The Motley Fool|

#artificial-intelligence #financeinvesting #healthcare

finance2 years ago•4 min saved

"Top 6 Dividend Stocks for Smart Investors in 2024"

Investing in dividend-paying stocks can provide regular cash payouts and potential for stock appreciation. Three smart dividend stocks to consider are Medtronic, offering a 3.3% dividend yield and consistent payout growth; Starbucks, with a 2.5% dividend yield and strong revenue growth; and PepsiCo, yielding 2.9% and boasting a long history of dividend increases. These stocks also have attractive valuations and potential for future growth, making them appealing options for investors looking to build a dividend-focused portfolio.

via The Motley Fool|

#dividend-stocks #finance #investing

financeinvesting2 years ago•4 min saved

"Top AI Healthcare Stocks for Investment"

The AI-in-healthcare market is set to reach over $148 billion by the end of the decade, presenting investment opportunities in healthcare companies leveraging AI. Two top stock picks in this space are Medtronic, a medical device giant with a focus on AI-driven products for surgical planning and diabetes management, and Moderna, known for its coronavirus vaccine and also heavily invested in AI for drug development, with both companies showing potential for significant growth in the future.

via The Motley Fool|

#artificial-intelligence #financeinvesting #healthcare

healthcare2 years ago•2 min saved

"Hospitals Introduce Innovative AFib Treatments with Tissue-Sparing Procedures"

Roper St. Francis in Charleston, S.C. is set to introduce an innovative treatment for atrial fibrillation (AFib) using Medtronic's pulsed ablation technology, which involves a less invasive catheter delivering electrical pulses to the heart to correct irregular heartbeats. Dr. Micheal Field, one of three doctors at Roper offering the procedure, anticipates shorter procedure times, better safety, and easier recovery for patients with AFib, and encourages those affected to discuss this new treatment option with their doctors.

via Live 5 News WCSC|

#afib #atrial-fibrillation #healthcare

business2 years ago•38 min saved

"Medtronic's Fiscal 2024 Performance and Strategic Shifts Drive Stock Surge"

Medtronic plc reported strong financial results for the third quarter of fiscal year 2024, with a 4.7% increase in worldwide revenue to $8.1 billion. The company saw growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and international markets, as well as a double-digit increase in Diabetes revenue. Medtronic raised its full-year guidance for organic revenue growth and EPS, and provided an update on its portfolio management and product approvals. The company also announced plans to exit its ventilator product line and combine the remaining Patient Monitoring & Respiratory Interventions businesses into a new unit called Acute Care and Monitoring.

via Medtronic|

#business #financial-results #healthcare

healthcare-conference2 years ago•6 min saved

"Key Highlights from J.P. Morgan Healthcare Conference 2024"

The 2024 J.P. Morgan Healthcare Conference featured updates from industry leaders including Medtronic, Abbott, Shockwave Medical, Dexcom, and Johnson & Johnson MedTech. Medtronic focused on restoring earnings power and highlighted growth opportunities in cardiac ablation, diabetes, and structural heart, while also announcing the creation of the Medtronic AI Center of Excellence. Abbott touted the success of its FreeStyle Libre continuous glucose monitoring device and its plans for further growth, while Shockwave Medical emphasized product launches and global expansion efforts. Dexcom unveiled its new Stelo sensor designed for people with type 2 diabetes, and Johnson & Johnson MedTech highlighted its growth through M&A activities and recent developments in surgical robotics and pulsed field ablation.

via Mass Device|

#abbott #dexcom #healthcare-conference

finance2 years ago•3 min saved

"Top 5 Dividend Stocks for Long-Term Passive Income in 2024"

In 2023, the S&P 500 index soared 24%, and the Dow Jones Industrial Average reached a new record high. Two dividend stocks, Medtronic and AbbVie, offer above-average yields and have the potential to maintain and raise their payouts in the coming decade. Medtronic, the world's largest medical device manufacturer, has earned regulatory approvals for multiple devices and expects adjusted earnings to cover its dividend payout. AbbVie, a biopharmaceutical company, has seen rising sales of its top-selling drugs and has new growth drivers to offset revenue losses from its lead drug, Humira. Both companies have the potential for dividend growth in the future.

via The Motley Fool|

#abbvie #dividend-stocks #finance

healthcare2 years ago•5 min saved

Medtronic's PulseSelect™ Pulsed Field Ablation System receives FDA approval for atrial fibrillation treatment

Medtronic has received FDA approval for its PulseSelect Pulsed Field Ablation (PFA) System, making it the first PFA technology to be approved. The system provides a safe and effective treatment for both paroxysmal and persistent atrial fibrillation (AF). It offers differentiated safety features, rapid pulmonary vein isolation, and a seamless transition to PFA in a clinician's workflow. The approval follows the recent European CE Mark of the PulseSelect PFA system. Commercialization is set to begin in early 2024.

via Medtronic|

#atrial-fibrillation #electrophysiology #fda-approval

business2 years ago•2 min saved

Medtronic's Turnaround Gains Momentum with Strong Q2 Performance

Medtronic's turnaround is showing signs of progress as the company beat Wall Street's expectations in its fiscal second-quarter report. The strong performance was driven by sales growth in its diabetes devices, particularly the MiniMed 780G, as well as its cardiovascular, neuroscience, and medical surgical portfolios. Medtronic also raised its outlook for full-year organic sales growth and adjusted profit. Analysts believe that the company's turnaround is becoming more tangible, although some investors may want to see more solid results before fully acknowledging the improvement.

via Investor's Business Daily|

#business #diabetes-devices #earnings

finance2 years ago•7 min saved

Veteran manager reveals top value stock picks for market success

The BNY Mellon Dynamic Value Fund, managed by Brian C. Ferguson, John Bailer, and Keith Howell, has a strong performance record and holds three standout value stocks: JPMorgan Chase, Medtronic, and Constellation Energy. Bailer believes these stocks are currently undervalued and offer good investment opportunities. The fund's approach combines intrinsic value, momentum, and strong quality fundamentals to avoid value traps. JPMorgan Chase is praised for its core strength and low valuation, Medtronic is seen as a high-quality stock with rising earnings estimates, and Constellation Energy is considered a renewable energy stock with low debt service.

via MarketWatch|

#bny-mellon-dynamic-value-fund #constellation-energy #finance